Form 4: Oruka Therapeutics SVP Sells Shares for Tax Obligations

Oruka Therapeutics' Senior Vice President of Finance, Arjun Agarwal, sold 395 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics, Inc. (ORKA), reported a transaction on March 16, 2026.
• Agarwal sold 395 shares of Oruka Therapeutics common stock at a price of $41.3 per share.
• The sale was executed as an automatic, non-discretionary 'sell-to-cover' procedure to satisfy tax withholding obligations arising from the vesting of restricted stock units.
• Following this transaction, Agarwal beneficially owns 18,863 shares of Oruka Therapeutics common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was pre-scheduled and non-discretionary.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this transaction as neutral. It is a routine, non-discretionary sale for tax purposes related to RSU vesting and does not indicate a change in management's confidence or the company's operational outlook.

Positives

• The transaction indicates the vesting of restricted stock units (RSUs), which is a form of executive compensation, suggesting that performance or time-based conditions for these awards were met.

Negatives

• No direct negatives for the company's operational performance are indicated by this routine, non-discretionary transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Oruka Therapeutics' future performance or strategic direction.

Management Comments

• The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are a common and routine practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, for executives to manage tax liabilities associated with the vesting of equity compensation like restricted stock units (RSUs). This mechanism allows executives to receive their vested shares while simultaneously fulfilling tax obligations without requiring personal cash outlays.

Comparison to Industry Standards

• This transaction aligns with standard industry practices for executive compensation and tax management. Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals frequently report similar 'sell-to-cover' transactions by their executives following RSU vesting, demonstrating this as a widely accepted and non-discretionary method for handling tax obligations on equity awards.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company fundamentals or management's long-term view.
• Employees: The vesting of RSUs is a positive for the executive, representing earned compensation.

Key Dates

Keywords

Oruka Therapeutics, ORKA, Form 4, Insider Transaction, Stock Sale, Tax Withholding, RSU Vesting, Arjun Agarwal, Sell-to-Cover, Executive Compensation